Brief: AB Science Announces Issuance Of European Patent For Masitinib
13/05/2024 17:11
May 13 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR
MASITINIB
IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL
2036
* THIS ORPHAN DRUG DESIGNATION PROVIDES 10 AND 7 YEARS OF
MARKET
EXCLUSIVITY IN EUROPE AND UNITED STATES RESPECTIVELY, SUBSEQUENT
TO APPROVAL
Source text for Eikon: urn:newsml:reuters.com:*:nGNX9L0WLZ
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease